Denali Therapeutics Inc (NASDAQ:DNLI) insider Ryan J. Watts sold 18,333 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $25.03, for a total value of $458,874.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Denali Therapeutics stock traded up $0.44 during mid-day trading on Friday, hitting $24.71. The company’s stock had a trading volume of 276,708 shares, compared to its average volume of 394,825. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -63.36 and a beta of 2.11. Denali Therapeutics Inc has a 1 year low of $12.32 and a 1 year high of $28.86.
Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Tuesday, March 12th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.90. The company had revenue of $125.68 million during the quarter, compared to analyst estimates of $9.73 million. Denali Therapeutics had a negative return on equity of 7.12% and a negative net margin of 28.06%. Equities research analysts predict that Denali Therapeutics Inc will post -1.69 earnings per share for the current fiscal year.
A number of equities research analysts have recently issued reports on DNLI shares. Zacks Investment Research upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research report on Tuesday, April 9th. ValuEngine lowered Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 20th.
WARNING: “Insider Selling: Denali Therapeutics Inc (DNLI) Insider Sells 18,333 Shares of Stock” was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/denali-therapeutics-inc-dnli-insider-ryan-j-watts-sells-18333-shares-of-stock.html.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.